Wealthfront Advisers LLC Makes New $53,000 Investment in Assertio Holdings, Inc. (NASDAQ:ASRT)

Wealthfront Advisers LLC acquired a new position in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 61,122 shares of the company’s stock, valued at approximately $53,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. CM Management LLC increased its holdings in Assertio by 23.1% during the 4th quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $348,000 after purchasing an additional 75,000 shares during the last quarter. Palumbo Wealth Management LLC grew its position in shares of Assertio by 10.6% in the 4th quarter. Palumbo Wealth Management LLC now owns 205,598 shares of the company’s stock worth $179,000 after acquiring an additional 19,637 shares in the last quarter. Empowered Funds LLC grew its position in shares of Assertio by 5.4% in the 4th quarter. Empowered Funds LLC now owns 455,282 shares of the company’s stock worth $397,000 after acquiring an additional 23,369 shares in the last quarter. Sonora Investment Management Group LLC acquired a new position in shares of Assertio in the 4th quarter worth approximately $39,000. Finally, Thurston Springer Miller Herd & Titak Inc. grew its position in shares of Assertio by 33.7% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 67,500 shares of the company’s stock worth $59,000 after acquiring an additional 17,000 shares in the last quarter. 48.96% of the stock is currently owned by hedge funds and other institutional investors.

Assertio Trading Down 1.5 %

NASDAQ:ASRT opened at $0.72 on Wednesday. Assertio Holdings, Inc. has a 12-month low of $0.68 and a 12-month high of $1.80. The firm has a market capitalization of $68.55 million, a P/E ratio of -0.98, a P/E/G ratio of 3.25 and a beta of 0.81. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.01 and a quick ratio of 1.57. The business has a 50 day simple moving average of $0.80 and a 200 day simple moving average of $0.96.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ASRT shares. Industrial Alliance Securities set a $1.75 target price on Assertio in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Assertio in a research report on Monday, December 16th. Finally, StockNews.com lowered Assertio from a “buy” rating to a “hold” rating in a research report on Monday.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.